Table 2.
Characteristics of patients with JIA-associated uveitis
| Patient Characteristics | |
|---|---|
| Patients, n (%) | 34 (6.8) |
| Sex, female, n (%) | 20 (58.8) |
| Duration between onset of arthritis and uveitis, years, mean ± SD | 1.8 ± 1.9 |
| oJIA | 1.9 ± 1.8 |
| ERA | 1.7 ± 2.1 |
| Poly JIA, RF– | 1.8 ± 3.0 |
| Onset of uveitis after JIA diagnosis,a years, n (%) | |
| 0–1 | 13 (38.2) |
| 1–2 | 4 (11.8) |
| 2–3 | 5 (14.7) |
| > 3 | 9 (26.5) |
| Affected eye,b n (%) | |
| Right only | 5 (17.2) |
| Left only | 8 (27.6) |
| Both | 16 (55.2) |
| Localization of uveitis,c n (%) | |
| Anterior | 19 (76) |
| Intermediate | 2 (8) |
| Posterior | 2 (8) |
| Panuveitis | 2 (8) |
| Categories of JIA/sex distribution, n (%) [female % within n] | |
| oJIA | 25 (73.5) [64] |
| poJIA | 20 (58.8) [65] |
| eoJIA | 5 (14.7) [60] |
| ERA | 6 (17.7) [9] |
| Poly JIA, RF– | 3 (8.8) [100] |
| ANA positivity, n/N (%) | 22/34 (64.7) |
| HLA-B27 positivity, n/N (%) | 3/10 (30) |
| Systemic treatments initiated after the diagnosis of uveitis, n (%) | |
| Methotrexate | 6 (17.6) |
| Azathioprine | 4 (11.8) |
| Sulfasalazine | 4 (11.8) |
| TNF-alpha inhibitors | 13 (38.2) |
| Tocilizumab | 3 (8.8) |
| Complications, n (%) | 5 (14.7) |
| Cataract | 4 (11.8) |
| Band keratopathy | 1 (2.9) |
ANA antinuclear antibody, eoJIA extended oJIA, ERA enthesitis-related arthritis, HLA human leucocyte antigen, JIA juvenile idiopathic arthritis, oJIA oligoarticular JIA, poJIA persistent oJIA, Poly JIA polyarticular JIA, RF rheumatoid factor, TNF tumor necrosis factor
a The diagnosis of uveitis preceded the diagnosis of JIA in 3 patients
b There were no data available for 5 patents
c There were no data available for 9 patients